Created On: 2020-07-15
Record Count: 17
- Technical Know How
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 255299
MGD013 is a first-in-class bispecific DART molecule designed to provide coordinate blockade of two immune checkpoint molecules expressed on T cells, PD-1 and LAG-3, for the potential treatment of a range of solid tumors and hematological malignancies.
IPSCIO Record ID: 184504
The original agreement entered into a broad, global alliance with the parties to discover, develop and commercialize novel immuno-therapeutics using the antibody platforms. The collaboration was initially focused on four CPM programs targeting GITR, OX40, TIM-3 and LAG-3, and in November 2015, was expanded by adding three novel undisclosed CPM targets.
GITR is an immune checkpoint agonist, one of a class of receptors that amplify the immune systemâ€™s response to cancer. GITR (glucocorticoid-induced TNFR-related protein) is a receptor expressed on select populations of T cells. Activation of GITR leads to a more powerful anti-tumor inflammatory response, increased production of inflammatory signaling molecules and increased resistance to immunosuppression.
OX40 (also known as CD134 and TNFRSF4), a member of the TNFR super-family, is an immune-response-enhancing receptor found on activated T cells. OX40 promotes proliferation of these activated T cells and prevents the immunosuppressive activity of inhibitory T cells. We believe that antibodies that activate OX40 may help increase immune system activity through both of these mechanisms. Furthermore, OX40 antibodies have the potential to work alone or in combination with other therapeutics. Combining with another agonist checkpoint antibody, which provides different, yet complementary signaling attributes may further augment anti-tumor responses.
IPSCIO Record ID: 27803
LAG-3 is a checkpoint protein expressed on the surface of certain cells of the immune system. LAG-3 (lymphocyte-activation gene 3) modulates signaling between immune cells and their targets. When LAG-3 is activated, the immune response is suppressed. Antibodies that block LAG-3 can block this inhibitory signal, thereby boosting the immune systemâ€™s response against cancer cells. LAG-3 acts synergistically with other checkpoint modulators. This suggests antibodies against LAG-3 may be valuable as combination therapies.
TIM-3 is a checkpoint receptor found on certain immune cells. TIM-3 stands for T-cell immunoglobulin and mucin domain-3. To prevent hyperactivation, natural ligands binding to TIM-3 reduce the activity of these immune cells. In some types of cancer, T cells express elevated levels of TIM-3, which results in excessive immune suppression. Blocking TIM-3 could stimulate immune responses and promote immune-mediated clearing of cancer cells. TIM-3 antibodies may have a role as a monotherapy and hold great potential in combination therapy, since they may help overcome resistance that patients may develop against other therapeutics.
IPSCIO Record ID: 266792
With this agreement, the Parties wish to resolve all existing and potential claims and outstanding obligations in connection with All Litigation Matters and desire to settle All Litigation Matters on the terms stated herein, without any admission of liability or wrongdoing, in order to avoid the time and expense of continuing to litigate All Litigation Matters.
Cetuximab is an antibody for use in combination with irinotecan in the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single-agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy.
11F8 is a fully-human monoclonal antibody which targets the human EGFR.
__-72000, also known as matuzumab, is a humanized EGFR-targeting monoclonal antibody.
IPSCIO Record ID: 211579
Antibodies targeting PD-1 have shown clinical efficacy in the treatment of various tumors. These antibodies act as checkpoint inhibitors, releasing the â€œbrakesâ€ on the immune system that are often imposed by tumors as a means to evade immune detection.
IPSCIO Record ID: 3068
IPSCIO Record ID: 203353
Licensor shall optimize and humanize the Candidate Molecules as set forth in the Research Plan. Licensor shall use its commercially reasonable efforts to perform its obligations under the Program in accordance with the Research Plan. Licensor shall provide the personnel, materials, equipment and other resources required to conduct its obligations under the Program. Licensor shall perform its obligations under the Program in accordance with high scientific and professional standards, and in compliance in all material respects with the requirements of applicable laws and regulations.
Licensee shall use its best efforts to actively research, develop and obtain regulatory approvals to market in major markets throughout the world at least one Product.
The Candidate Molecules shall mean, collectively, monoclonal antibody (mAb) HUIV26 and mAb HUI77 as provided by Licensee to Licensor.
Materials shall mean the Candidate Molecules, DNA sequence information and the cDNA to encode Candidate Molecules and the hybridoma cell lines expressing the Candidate Molecules.
Program Antibody shall mean the optimized and humanized compositions of matter developed under the Program, and the cDNA encoding such compositions of matter, delivered to Licensee.
Licensor utilizes its technology to humanize a murine monoclonal antibody, which is now referred to as D93, and another of our anti-angiogenic monoclonal antibodies.
D93 is humanized, anti-angiogenic monoclonal antibody, in patients with solid tumors.
IPSCIO Record ID: 256273
This agreement includes a non-exclusive grant by Licensee to Licensor.
The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.
Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.
IPSCIO Record ID: 252203
LIBTAYOÂ® is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
Cutaneous squamous cell carcinoma (cSCC) is a type of skin cancer.
IPSCIO Record ID: 247069
IPSCIO Record ID: 296181
The November amendment adds an additional dual-reactive antibody product candidate.
The AnaptysBio platform offers unmatched capabilities in antibody discovery, generation and optimization, and we are excited about the potential for these programs. We look forward to working with the AnaptysBio team to develop novel immuno-oncology-based approaches to a variety of tumors.
IPSCIO Record ID: 74574
IPSCIO Record ID: 246211
INB03 is a novel innate immune system check-point inhibitor that targets Myeloid Derived Suppressor Cells.
Myeloid Derived Suppressor Cells (MDSC) of the innate immune system are often increased in patients with cancer. The level of MDSC in the blood or the tumor microenvironment predict severity of disease, risk of dying from the cancer, and the failure of other immunotherapy treatment strategies such as currently available check point inhibitors. The MDSC secrete immunosuppressive cytokines that protect the tumor from attack by the patient's immune system. Strategies that target MDSC are needed to continue to make progress in the treatment of cancer.
IPSCIO Record ID: 26237
Patent: Antigen binding proteins that bind PD-L1
IPSCIO Record ID: 256253
Licensor grants the French Licensee an exclusive right and license, with the right to grant sub licenses, under Licensed Technology and Licensed Patent Rights, including Licensors rights to Joint Technology and Joint Patent Rights, to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, have sold, import and export Collaboration Compounds and Licensed Products in the Field in the Territory.
This agreement includes a non-exclusive grant-back from Licensee to Licensor.
MM-121 is a monoclonal antibody designed to block signaling of the ErbB3 receptor, a member of the epidermal growth factor (EGF) receptor family.
The Collaboration Compound means MM121, or, any antibody fragment of MM-121, including any Fab, F(ab)2, Fv, and scFv fragments, or the primary molecular target of which is ErbB3. ErbB3, also known as HER3, is a transmembrane receptor belonging to the epidermal growth factor (EGF) receptor family.
MM-121 is currently in Phase 1 clinical testing.
Licensed Technology means the Diagnostic Technology and the Therapeutic Technology.
MM-121 a genetically engineered antibody designed to block a receptor on cells known as ErbB3. Thatâ€™s thought to be an important new target for cancer drugs, because itâ€™s a member of the epidermal growth factor receptor family of proteins, which are known to amplify cell proliferation that can give rise to out-of-control tumors.
The ErbB3 receptor is a novel target known to be a key mediator of signaling in the ErbB pathway (also known as the EGFR or HER pathway) â€“ a signaling network that impacts a broad array of cancers. By targeting ErbB3, MM-121 is believed to have a broad application across cancer as both a monotherapy and in combination with other therapeutics.
IPSCIO Record ID: 26536
IPSCIO Record ID: 260705